EGFR 19-del和L858R突变型NSCLC患者预后比较

被引：5

作者：

韦文娥 ^{[1
]}

利基林 ^{[1
]}

宁淑芳 ^{[1
]}

刘海洲 ^{[1
]}

蔡政民 ^{[1
]}

张力图 ^{[1
]}

机构：

[1] 广西医科大学附属肿瘤医院

来源：

山东医药 | 2016年 / 56卷 / 17期

关键词：

肺肿瘤; 表皮生长因子受体突变; 19外显子突变; 21外显子L858R突变; 预后分析;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

目的比较表皮生长因子受体(EGFR)19外显子(19-del)突变和21外显子L858R点突变型非小细胞肺癌(NSCLC)患者的预后。方法收集257例NSCLC患者,取其新鲜组织或石蜡包埋组织,采用ARMS-PCR法检测EGFR基因型。收集临床资料,定期随访,以死亡为终点事件,失访或截止至末次随访时间尚未发生终点事件均纳入截尾数据,应用SPSS17.0软件进行统计分析。结果在257例患者中,19-del突变型134例,L858R突变型123例。两种类型突变患者的临床特征分布比较,P均>0.05。生存分析结果显示,19-del突变型中位生存期为798 d,L858R突变型中位生存期为710 d,两者的总生存期差异无统计学意义(P>0.05)。进一步对样本进行分层分析结果显示,在汉族患者中,19-del突变型患者预后比L858R突变型患者好(P=0.047),在壮族中未观察到差异有统计学意义(P>0.05)。在不同年龄、性别、TNM分期和临床分期上预后也没有统计学差异(P均>0.05)。结论EGFR 19-del突变和L858R突变型NSCLC患者总体上总生存期相似,但是在汉族中EGFR 19-del型突变患者预后较好。

引用

页码：22 / 25

页数：4

共 6 条

[1] Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
Zhu, Jian-Quan
Zhong, Wen-Zhao
Zhang, Guo-Chun
Li, Rong
Zhang, Xu-Chao
Guo, Al-Lin
Zhang, Yi-Fang
An, She-juan
Mok, Tony S.
Wu, Yi-Long
[J]. CANCER LETTERS, 2008, 265 (02) : 307 - 317
[2] Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas[J] . Bin Gao,Yihua Sun,Junhua Zhang,Yan Ren,Rong Fang,Xiangkun Han,Lei Shen,Xin-yuan Liu,William Pao,Haiquan Chen,Hongbin Ji. &nbspJournal of Thoracic Oncology . 2010 (8)
[3] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J] . &nbspLancet Oncology . 2012 (3)
[4] Global cancer statistics, 2012[J] . Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet‐Tieulent,Ahmedin Jemal. &nbspCA: A Cancer Journal for Clinicians . 2015 (2)
[5] Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment[J] . Justine L. Kuiper,Danielle A.M. Heideman,Tom Würdinger,Katrien Grünberg,Harry J.M. Groen,Egbert F. Smit. &nbspClinical Lung Cancer . 2014
[6] Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Non–Small-Cell Lung Cancer[J] . Yan-yan He,Xu-chao Zhang,Jin-ji Yang,Fei-yu Niu,Zhu Zeng,Hong-hong Yan,Chong-rui Xu,Ji-lin Guan,Wen-zhao Zhong,Lu-lu Yang,Long-hua Guo,Yi-long Wu. &nbspClinical Lung Cancer . 2014 (6)

← 1 →